AKT1 and liver cancer: It has been found that cancers with activated PI3K/Akt signaling become more aggressive, and in clinical liver cancer patients, activation of the AKT pathway is an important indicator of risk for an early relapse and an unfavorable outcome (Tang et al., 2022).